UTHR

UTHR

USD

United Therapeutics Corporation Common Stock

$437.330+4.580 (1.058%)

即時價格

Healthcare
Drug Manufacturers - Specialty & Generic
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$432.750

最高

$440.000

最低

$430.020

交易量

0.35M

公司基本面

市值

18.8B

行業

Drug Manufacturers - Specialty & Generic

國家

United States

交易統計

平均交易量

0.79M

交易所

NMS

貨幣

USD

52週範圍

最低 $266.98當前 $437.330最高 $479.5

相關新聞

BusinessWire

United Therapeutics Corporation to Present at Upcoming Investor Conferences

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that company executives will provide an overview and update on the company during fireside chat sessions at two upcoming

查看更多
United Therapeutics Corporation to Present at Upcoming Investor Conferences
BusinessWire

United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease

Ongoing EXPAND Study is the First Clinical Trial to Evaluate Xenotransplantation in End-Stage Renal Disease United Therapeutics Corporation (Nasdaq: UTHR) today announced the first clinical xenotransplantation in its

查看更多
United Therapeutics Corporation Announces First Transplant in EXPAND Clinical Trial of UKidney in Patients With End-Stage Renal Disease
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $525

HC Wainwright & Co. analyst Andrew S. Fein maintains United Therapeutics with a Buy and raises the price target from $500 to $525.

查看更多
HC Wainwright & Co. Maintains Buy on United Therapeutics, Raises Price Target to $525
Analyst Upgrades

RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $587

RBC Capital analyst Lisa Walter maintains United Therapeutics with a Outperform and raises the price target from $569 to $587.

查看更多
RBC Capital Maintains Outperform on United Therapeutics, Raises Price Target to $587
Analyst Upgrades

Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $423

Wells Fargo analyst Benjamin Burnett maintains United Therapeutics with a Equal-Weight and raises the price target from $414 to $423.

查看更多
Wells Fargo Maintains Equal-Weight on United Therapeutics, Raises Price Target to $423
BusinessWire

United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key

BusinessWire

United Therapeutics Corporation to Report Third Quarter 2025 Financial Results Before Market Open on Wednesday, October 29, 2025

United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly